ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter

Pola Orbis fails to savor record profit as suspicion swirls

Tokyo-based cosmetics maker stalls in Asian markets as forgery rumors hound president

Pola Orbis' successful new anti-wrinkle cream helped draw 500 more people to its shareholders meeting March 27 than last year.

TOKYO -- Despite a record 2017 profit, Japanese cosmetics company Pola Orbis Holdings is being forced to walk a precarious path with shareholders as suspicion over a family inheritance gains new life and sales struggle in Asian markets.

The Pola Wrinkle Shot Serum facial treatment product has been a big hit among middle-aged and elderly women, driving the company's brisk earnings last year. President Satoshi Suzuki could have boasted about his decision to take a long view and spend 15 years to develop the product. Its first-year sales reached about 13 billion yen ($122 million).

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more